

Notice Regarding the Publication of a Research Paper on SI-449 (cs barrier[®]), an Adhesion Barrier

Seikagaku Corporation hereby announces that a research paper by the National Cancer Center Japan (President: Hiroyuki Mano; located in Chuo-ku, Tokyo) on the efficacy and safety results obtained from a clinical trial conducted in Japan of SI-449 (product name: "cs barrier[®]"), a surgical adhesion barrier developed by the Company, has been published in JAMA Surgery, one of the world's leading medical journals in the field of surgery.

For details of the research paper, please refer to the publication information or the information published today on the National Cancer Center Japan website.

Publication Details

Journal: JAMA Surgery

Title: Cross-linked Chondroitin Sulfate Adhesion Barrier System in Open Rectal Resection

Authors: Yukihide Kanemitsu et al.

DOI: 10.1001/jamasurg.2026.3416

Publication Date: August 26, 2026 (U.S. Time)

Article Website (external link): <https://doi.org/10.1001/jamasurg.2026.3416>

National Cancer Center Japan

Research Paper Introduction Page (Link to an external Japanese-language website):

<https://www.ncc.go.jp/jp/information/researchtopics/2026/0929/index.html>

#####

Disclaimer

This press release contains information regarding the product; however, such information is intended solely to provide information to investors, shareholders, members of the press, and other stakeholders, and is not intended to promote, advertise, or solicit the efficacy, safety, performance, or any other attributes of any pharmaceutical products or medical devices, including products under development.

In addition, the approval status and product information of the product may vary depending on the country or region, and the product is not sold in all countries and regions.